Simon Jennings
- No significant clinical drug-drug interaction potential with indacaterolBy Sheryl Perry, Paul Goldsmith, Sivakumar Vaidyanathan, Prafulla Bhad, Heidi Einolf, Ralph Woessner, Guenther Kaiser, Simon Jennings and Beverley PattersonSheryl Perry1DMPK, Novartis Institutes of BioMedical Research, Horsham, United KingdomPaul Goldsmith1DMPK, Novartis Institutes of BioMedical Research, Horsham, United KingdomSivakumar Vaidyanathan2Translational Sciences, Novartis Institutes of BioMedical Research, Hyderabad, IndiaPrafulla Bhad2Translational Sciences, Novartis Institutes of BioMedical Research, Hyderabad, IndiaHeidi Einolf3DMPK, Novartis Institutes of BioMedical Research, East Hanover, NJ, United StatesRalph Woessner4DMPK, Novartis Institutes of BioMedical Research, Basel, SwitzerlandGuenther Kaiser4DMPK, Novartis Institutes of BioMedical Research, Basel, SwitzerlandSimon Jennings5Development, Novartis Horsham Research Centre, Horsham, United KingdomBeverley Patterson1DMPK, Novartis Institutes of BioMedical Research, Horsham, United Kingdom
Buying books on this site
Purchases made on this website are of electronic books only.
About the ERS books
The ERS Monograph is the quarterly book series from the European Respiratory Society. Each Monograph covers a specific area of respiratory medicine, providing in-depth reviews that give clinicians at all levels a concise, comprehensive guide to symptoms, diagnosis and treatment.
The ERS Handbooks are compact guides to broad areas of the respiratory field. Launched in 2010, the series now covers adult, paediatric and sleep respiratory medicine, includes a companion volume of self-assessment questions and features the ERS Practical Handbooks.